Capecitabine tablets: clinical trials recruiting now

Phase breakdown

Conditions being studied

Recruiting trials involving Capecitabine tablets

• A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer
  NCT06202261 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer
  NCT07679360 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery
  NCT05973864 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 20 locations
• Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease
  NCT05800275 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 11 locations
• JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
  NCT06079983 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 87 locations
• Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer
  NCT06255392 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: Female · 1 location

Common questions

How many recruiting trials involve Capecitabine tablets?

6 recruiting trials across 11 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.